JP2022141692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022141692A5 JP2022141692A5 JP2022105683A JP2022105683A JP2022141692A5 JP 2022141692 A5 JP2022141692 A5 JP 2022141692A5 JP 2022105683 A JP2022105683 A JP 2022105683A JP 2022105683 A JP2022105683 A JP 2022105683A JP 2022141692 A5 JP2022141692 A5 JP 2022141692A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- stereoisomer
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 31
- 239000012453 solvate Substances 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- -1 C 1-6 alkyl-OR 7 Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024020785A JP2024056887A (ja) | 2017-03-13 | 2024-02-15 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2025205384A JP2026035720A (ja) | 2017-03-13 | 2025-11-27 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470830P | 2017-03-13 | 2017-03-13 | |
| US62/470,830 | 2017-03-13 | ||
| PCT/US2018/022049 WO2018169880A1 (en) | 2017-03-13 | 2018-03-12 | Dual magl and faah inhibitors |
| JP2019572352A JP7178375B2 (ja) | 2017-03-13 | 2018-03-12 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572352A Division JP7178375B2 (ja) | 2017-03-13 | 2018-03-12 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020785A Division JP2024056887A (ja) | 2017-03-13 | 2024-02-15 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022141692A JP2022141692A (ja) | 2022-09-29 |
| JP2022141692A5 true JP2022141692A5 (https=) | 2023-02-10 |
| JP7440572B2 JP7440572B2 (ja) | 2024-02-28 |
Family
ID=63445929
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572352A Active JP7178375B2 (ja) | 2017-03-13 | 2018-03-12 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2022014178A Active JP7781660B2 (ja) | 2017-03-13 | 2022-02-01 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2022105683A Active JP7440572B2 (ja) | 2017-03-13 | 2022-06-30 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2024020785A Pending JP2024056887A (ja) | 2017-03-13 | 2024-02-15 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2025205384A Pending JP2026035720A (ja) | 2017-03-13 | 2025-11-27 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572352A Active JP7178375B2 (ja) | 2017-03-13 | 2018-03-12 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2022014178A Active JP7781660B2 (ja) | 2017-03-13 | 2022-02-01 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020785A Pending JP2024056887A (ja) | 2017-03-13 | 2024-02-15 | デュアルｍａｇｌ及びｆａａｈインヒビター |
| JP2025205384A Pending JP2026035720A (ja) | 2017-03-13 | 2025-11-27 | デュアルｍａｇｌ及びｆａａｈインヒビター |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10350205B2 (https=) |
| EP (3) | EP4424683A3 (https=) |
| JP (5) | JP7178375B2 (https=) |
| KR (3) | KR102613364B1 (https=) |
| CN (5) | CN117736178B (https=) |
| AR (2) | AR111271A1 (https=) |
| AU (3) | AU2018236161B9 (https=) |
| CA (2) | CA3299704A1 (https=) |
| CL (1) | CL2019002583A1 (https=) |
| CO (1) | CO2019009932A2 (https=) |
| DK (1) | DK3595665T3 (https=) |
| EA (1) | EA201991898A1 (https=) |
| EC (1) | ECSP19066721A (https=) |
| ES (1) | ES2994239T3 (https=) |
| FI (1) | FI3595665T3 (https=) |
| HR (1) | HRP20241558T1 (https=) |
| HU (1) | HUE069115T2 (https=) |
| IL (3) | IL301334B2 (https=) |
| LT (1) | LT3595665T (https=) |
| MX (1) | MX2022006862A (https=) |
| NZ (4) | NZ797702A (https=) |
| PL (1) | PL3595665T3 (https=) |
| PT (1) | PT3595665T (https=) |
| RS (1) | RS66192B1 (https=) |
| SA (2) | SA523450367B1 (https=) |
| SG (1) | SG11201908159QA (https=) |
| SI (1) | SI3595665T1 (https=) |
| SM (1) | SMT202400468T1 (https=) |
| TW (2) | TWI874919B (https=) |
| WO (1) | WO2018169880A1 (https=) |
| ZA (1) | ZA201905934B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| NZ797702A (en) * | 2017-03-13 | 2026-03-27 | Lundbeck La Jolla Research Center Inc | Dual magl and faah inhibitors |
| SMT202400369T1 (it) * | 2018-09-13 | 2024-11-15 | Celgene Corp | (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometossi)benzil)piperazin-1-carbossilato cristallino, sue composizioni e relativi metodi di utilizzo |
| ES2955037T3 (es) | 2018-11-22 | 2023-11-28 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| JP2023158387A (ja) * | 2022-04-18 | 2023-10-30 | 株式会社三洋物産 | 遊技機 |
| JP2023158385A (ja) * | 2022-04-18 | 2023-10-30 | 株式会社三洋物産 | 遊技機 |
| JP2023158388A (ja) * | 2022-04-18 | 2023-10-30 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1636187A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase |
| BRPI0410654A (pt) * | 2003-06-12 | 2006-06-20 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
| JP2006088075A (ja) * | 2004-09-27 | 2006-04-06 | Kubota Corp | 脱臭装置 |
| ES2528674T3 (es) * | 2005-02-17 | 2015-02-11 | Astellas Pharma Inc. | Piperidina y carboxilatos de piperacina como inhibidores de FAAH |
| US7915251B2 (en) * | 2005-03-18 | 2011-03-29 | Institute For Chemical Genomics | Alpha-helix mimetics and methods relating to the treatment of fibrosis |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| US8461159B2 (en) * | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| FR2945531A1 (fr) * | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2010141817A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| BR112012018913A2 (pt) * | 2010-01-28 | 2017-06-20 | Merck Sharp & Dohme | "composição farmacêutica, e, uso da composição" |
| TW201206440A (en) | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| NZ723198A (en) | 2012-11-20 | 2018-11-30 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds and compositions and methods of using thereof |
| WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| JP6647592B2 (ja) | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| WO2015116774A1 (en) * | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| US10570146B2 (en) * | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| JP2018513119A (ja) | 2015-03-18 | 2018-05-24 | アビデ セラピューティクス，インク． | ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法 |
| TN2017000544A1 (en) * | 2015-07-31 | 2019-04-12 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| US10781211B2 (en) | 2016-05-12 | 2020-09-22 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| NZ797702A (en) * | 2017-03-13 | 2026-03-27 | Lundbeck La Jolla Research Center Inc | Dual magl and faah inhibitors |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
-
2018
- 2018-03-12 NZ NZ797702A patent/NZ797702A/en unknown
- 2018-03-12 ES ES18768237T patent/ES2994239T3/es active Active
- 2018-03-12 CN CN202311430611.5A patent/CN117736178B/zh active Active
- 2018-03-12 JP JP2019572352A patent/JP7178375B2/ja active Active
- 2018-03-12 NZ NZ756915A patent/NZ756915A/en unknown
- 2018-03-12 EP EP24190031.5A patent/EP4424683A3/en active Pending
- 2018-03-12 CN CN202311430583.7A patent/CN118271288A/zh active Pending
- 2018-03-12 IL IL301334A patent/IL301334B2/en unknown
- 2018-03-12 HR HRP20241558TT patent/HRP20241558T1/hr unknown
- 2018-03-12 CN CN202311430784.7A patent/CN117510468A/zh active Pending
- 2018-03-12 CA CA3299704A patent/CA3299704A1/en active Pending
- 2018-03-12 FI FIEP18768237.2T patent/FI3595665T3/fi active
- 2018-03-12 SG SG11201908159Q patent/SG11201908159QA/en unknown
- 2018-03-12 SM SM20240468T patent/SMT202400468T1/it unknown
- 2018-03-12 PL PL18768237.2T patent/PL3595665T3/pl unknown
- 2018-03-12 CN CN201880017546.4A patent/CN110709084A/zh active Pending
- 2018-03-12 CN CN202311430576.7A patent/CN117466868A/zh active Pending
- 2018-03-12 PT PT187682372T patent/PT3595665T/pt unknown
- 2018-03-12 KR KR1020197029778A patent/KR102613364B1/ko active Active
- 2018-03-12 WO PCT/US2018/022049 patent/WO2018169880A1/en not_active Ceased
- 2018-03-12 CA CA3056076A patent/CA3056076A1/en active Pending
- 2018-03-12 SI SI201831175T patent/SI3595665T1/sl unknown
- 2018-03-12 IL IL311446A patent/IL311446B2/en unknown
- 2018-03-12 EA EA201991898A patent/EA201991898A1/ru unknown
- 2018-03-12 KR KR1020257001192A patent/KR20250016458A/ko active Pending
- 2018-03-12 HU HUE18768237A patent/HUE069115T2/hu unknown
- 2018-03-12 KR KR1020237042581A patent/KR102756049B1/ko active Active
- 2018-03-12 EP EP23214453.5A patent/EP4335848A3/en active Pending
- 2018-03-12 AU AU2018236161A patent/AU2018236161B9/en active Active
- 2018-03-12 US US15/919,113 patent/US10350205B2/en active Active
- 2018-03-12 DK DK18768237.2T patent/DK3595665T3/da active
- 2018-03-12 NZ NZ796461A patent/NZ796461A/en unknown
- 2018-03-12 EP EP18768237.2A patent/EP3595665B1/en active Active
- 2018-03-12 NZ NZ797704A patent/NZ797704A/en unknown
- 2018-03-12 RS RS20241273A patent/RS66192B1/sr unknown
- 2018-03-12 LT LTEPPCT/US2018/022049T patent/LT3595665T/lt unknown
- 2018-03-13 TW TW112106986A patent/TWI874919B/zh active
- 2018-03-13 TW TW107108499A patent/TWI797111B/zh active
- 2018-03-13 AR ARP180100579A patent/AR111271A1/es unknown
-
2019
- 2019-06-04 US US16/431,632 patent/US11129827B2/en active Active
- 2019-09-04 IL IL269119A patent/IL269119B2/en unknown
- 2019-09-09 ZA ZA2019/05934A patent/ZA201905934B/en unknown
- 2019-09-10 CL CL2019002583A patent/CL2019002583A1/es unknown
- 2019-09-11 SA SA523450367A patent/SA523450367B1/ar unknown
- 2019-09-11 SA SA519410101A patent/SA519410101B1/ar unknown
- 2019-09-12 CO CONC2019/0009932A patent/CO2019009932A2/es unknown
- 2019-09-12 MX MX2022006862A patent/MX2022006862A/es unknown
- 2019-09-13 EC ECSENADI201966721A patent/ECSP19066721A/es unknown
-
2021
- 2021-08-25 US US17/412,102 patent/US12318383B2/en active Active
-
2022
- 2022-02-01 JP JP2022014178A patent/JP7781660B2/ja active Active
- 2022-04-26 AR ARP220101083A patent/AR125457A2/es unknown
- 2022-05-25 AU AU2022203557A patent/AU2022203557B2/en active Active
- 2022-06-30 JP JP2022105683A patent/JP7440572B2/ja active Active
-
2023
- 2023-07-04 AU AU2023204293A patent/AU2023204293A1/en not_active Abandoned
-
2024
- 2024-02-15 JP JP2024020785A patent/JP2024056887A/ja active Pending
-
2025
- 2025-05-02 US US19/197,599 patent/US20250262205A1/en active Pending
- 2025-11-27 JP JP2025205384A patent/JP2026035720A/ja active Pending